Table 5.
Risk Factors for Significant (≥10%) Weight Gain in Individuals Initiating Antiretroviral Therapy
| Variable | OR | (95% CI) | P Value |
|---|---|---|---|
| CD4 count (<200 vs ≥200 cells/all) | 4.36 | (3.6–5.27) | <.001 |
| HIV RNA (>100K vs ≤100K copies/mL) | 1.98 | (1.65–2.37) | <.001 |
| BMI | |||
| Normal vs overweight | 1.54 | (1.27–1.87) | <.001 |
| Normal vs obese | 1.66 | (1.29–2.15) | <.001 |
| Sex (female vs male) | 1.54 | (1.21–1.96) | <.001 |
| Race (black vs non-black) | 1.32 | (1.10–1.59) | .003 |
| Third ART agent | |||
| BIC/DTG vs EFV | 1.82 | (1.24–2.66) | .002 |
| EVG/c vs EFV | 1.36 | (1.04–1.78) | .026 |
| RPV vs EFV | 1.51 | (1.03–2.20) | .035 |
| ATV/r vs EFV | 0.92 | (.59–1.45) | .73 |
| NRTI | |||
| TAF vs ZDV | 1.75 | (1.04–2.95) | .034 |
| TDF vs ZDV | 1.19 | (.76–1.87) | .44 |
| ABC vs ZDV | 0.93 | (.47–1.8) | .82 |
| TAF vs ABC | 1.9 | (1.25–2.88) | .003 |
| TDF vs ABC | 1.29 | (.79–2.11) | .31 |
| TAF vs TDF | 1.47 | (1.14–1.90) | .003 |
Stepwise model selection was used to identify which baseline risk factors were associated with significant (≥10%) weight gain in individuals initiating ART. As a result, CD4 cell count, HIV RNA, BMI, sex, and race were selected. ORs and their 95% CIs and P values were from the logistic regression model including baseline categories of CD4 cell count, HIV-1 RNA, BMI, sex, and race as risk factors, with third agent and NRTIs as fixed effects.
Abbreviations: ABC, abacavir; ART, antiretroviral therapy; ATV/r, ritonavir-boosted atazanavir; BIC, bictegravir; BMI, body mass index; CI, confidence interval; DTG, dolutegravir; EFV, efavirenz; EVG/c, cobicistat-boosted elvitegravir; HIV, human immunodeficiency virus; NRTI, nucleoside reverse transcriptase inhibitor; OR, odds ratio; RPV, rilpivirine; TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate; ZDV, zidovudine.